In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development
In this short video, InMed’s CEO, Eric A. Adams, provides a summary of the preclinical studies of INM-901, the company’s drug candidate in the potential
In this Fierce Biotech article, we learn about how the preclinical results of INM-901 indicate that this drug candidate may address multiple pathologies related to
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields